| 4.34 -0.1 (-2.25%) | 04-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 5.69 | 1-year : | 6.28 |
| Resists | First : | 4.87 | Second : | 5.38 |
| Pivot price | 4.67  |
|||
| Supports | First : | 4.07 | Second : | 3.38 |
| MAs | MA(5) : | 4.64 |
MA(20) : | 4.65 |
| MA(100) : | 3.43 |
MA(250) : | 2.23 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 32.2 |
D(3) : | 45.4 |
| RSI | RSI(14): 45 |
|||
| 52-week | High : | 6.03 | Low : | 0.36 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ADCT ] has closed above bottom band by 13.1%. Bollinger Bands are 31.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.5 - 4.54 | 4.54 - 4.57 |
| Low: | 4.14 - 4.18 | 4.18 - 4.2 |
| Close: | 4.29 - 4.35 | 4.35 - 4.39 |
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL in second-line transplant-ineligible patients; and Phase I clinical trial for treatment of relapsed or refractory non-hodgkin lymphoma (NHL). The company is also developing camidanlumab tesirine, an ADC that has completed Phase I clinical trial to treat relapsed or refractory NHL; in Phase II clinical trial in relapsed or refractory hodgkin lymphoma; and in Phase Ib clinical trial for selected advanced solid tumors. In addition, it develops ADCT-602, which is in Phase Ia clinical trial for treatment of acute lymphoblastic leukemia; ADCT-601 and ADCT-901 that are in Phase Ia clinical trial for treatment of various solid tumors; and preclinical product candidates, including ADCT-701 and ADCT-901 for the treatment of solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.
Mon, 22 Apr 2024
Brokerages Set ADC Therapeutics SA (NYSE:ADCT) Price Target at $7.50 - MarketBeat
Wed, 03 Apr 2024
ADC Therapeutics to Host a Virtual Research Investor Event on Tuesday, April 9, 2024 - GlobeNewswire
Tue, 19 Mar 2024
ADC Therapeutics: Real Opportunity With Real Risk In 2024 (NYSE:ADCT) - Seeking Alpha
Sun, 17 Mar 2024
ADC Therapeutics SA's (NYSE:ADCT) 29% Dip In Price Shows Sentiment Is Matching Revenues - Simply Wall St
Sat, 16 Mar 2024
US$10.00 - That's What Analysts Think ADC Therapeutics SA (NYSE:ADCT) Is Worth After These Results - Yahoo Finance
Fri, 15 Mar 2024
ADC Therapeutics SA (NYSE:ADCT) Q4 2023 Earnings Call Transcript - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 83 (M) |
| Shares Float | 63 (M) |
| Held by Insiders | 29 (%) |
| Held by Institutions | 41.1 (%) |
| Shares Short | 993 (K) |
| Shares Short P.Month | 869 (K) |
| EPS | -2.95 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -1.8 |
| Profit Margin | 0 % |
| Operating Margin | -221.7 % |
| Return on Assets (ttm) | -24.6 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | -76 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.84 |
| EBITDA (p.s.) | -2 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -119 (M) |
| Levered Free Cash Flow | -80 (M) |
| PE Ratio | -1.48 |
| PEG Ratio | -0.2 |
| Price to Book value | -2.42 |
| Price to Sales | 5.14 |
| Price to Cash Flow | -3.02 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|